FDA Grants Appeal for Ardelyx’s XPHOZAH® (tenapanor)
- Thursday, December 29, 2022, 7:13
- Environment
- Add a comment
Office of New Drugs directs the Division of Cardiology and Nephrology to work with Ardelyx to develop a label to support the commercialization of XPHOZAH; Ardelyx to resubmit NDA in the first half of 2023 Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor,…
About the Author
adminasapcorp has written 38990 stories on this site.